These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1845151)

  • 1. Enzyme replacement therapy in type I Gaucher disease.
    Kay AC; Saven A; Garver P; Thurston DW; Rosenbloom BF; Beutler E
    Trans Assoc Am Physicians; 1991; 104():258-64. PubMed ID: 1845151
    [No Abstract]   [Full Text] [Related]  

  • 2. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
    Parco S; Bruno G; Durighello M; Giorgini R; Simeone R; Bembi B
    Haematologica; 1999 Apr; 84(4):376-7. PubMed ID: 10190956
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzyme replacement in Gaucher disease.
    Beutler E
    PLoS Med; 2004 Nov; 1(2):e21. PubMed ID: 15578103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y; Ali AS
    J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
    Burrow TA; Cohen MB; Bokulic R; Deutsch G; Choudhary A; Falcone RA; Grabowski GA
    J Pediatr; 2007 Feb; 150(2):202-6. PubMed ID: 17236903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme augmentation in moderate to life-threatening Gaucher disease.
    Fallet S; Grace ME; Sibille A; Mendelson DS; Shapiro RS; Hermann G; Grabowski GA
    Pediatr Res; 1992 May; 31(5):496-502. PubMed ID: 1603627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
    Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
    Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P; Drugan C; Cret V; Al-Kzouz C; Denes C; Coldea C; Zimmermann A
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-replacement therapy for Gaucher's disease.
    N Engl J Med; 1991 Dec; 325(25):1809-11. PubMed ID: 1944489
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
    Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI; Giraldo P; Giralt M
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic targets in Gaucher's disease].
    Giraldo P; Roca M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():46-9. PubMed ID: 22230126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound hepatosplenomegaly in type 1 Gaucher disease.
    Tóth J; Erdos M; Maródi L
    Eur J Haematol; 2003 Feb; 70(2):125-8. PubMed ID: 12581195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
    Beutler E
    Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
    [No Abstract]   [Full Text] [Related]  

  • 18. Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.
    Sato Y; Beutler E
    J Clin Invest; 1993 May; 91(5):1909-17. PubMed ID: 8486762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Gaucher's disease with OGT 918.
    Mistry PK
    Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
    [No Abstract]   [Full Text] [Related]  

  • 20. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
    Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.